Professor Peter Openshaw discusses Respiratory Syncytial Virus Infection (RSV). RSV is a common respiratory virus that usually causes mild, cold-like symptoms in most adults but it is the leading cause of hospitalisation in babies Step into the world of groundbreaking medical research with the latest episode of our podcast as Sir Andrew Pollard engages in a riveting conversation with the esteemed Professor Peter Openshaw from Imperial University. Peter Openshaw is a respiratory physician and mucosal immunologist researcher, studying how the immune system both protects against viral infection but also causes disease. He has run studies of human experimental infection of volunteers since 2008 and is Director of the HIC-Vac consortium established to accelerate vaccine development for pathogens of high global impact.
Delving deep into the realm of Respiratory Syncytial Virus (RSV) infection, this episode unveils the complexities of a common respiratory virus that can escalate into a serious health concern. RSV is a common respiratory virus that usually causes mild, cold-like symptoms in most adults but it can become more severe and it is the leading cause of hospitalisation in babies.
In this illuminating dialogue, listeners are treated to a comprehensive exploration of RSV, from its seemingly innocuous cold-like symptoms to its potential for severe illness, particularly in vulnerable populations. The conversation navigates through Professor Openshaw's early investigations into immune responses, his fascination with inflammatory reactions, and the transformative advancements witnessed in RSV medical research over the years.
As the episode progresses, attention turns to the horizon of medical innovation, with a thoughtful examination of the challenges inherent in vaccine trials and the tantalising prospect of novel treatments for infectious diseases like RSV. Join Sir Andrew Pollard and Professor Peter Openshaw as they peer into the future, offering a glimpse of what lies ahead in the relentless pursuit of conquering respiratory ailments. Creative Commons Attribution-Non-Commercial-Share Alike 2.0 UK: England & Wales; http://creativecommons.org/licenses/by-nc-sa/2.0/uk/
All content for The Oxford Colloquy is the property of Oxford University and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Professor Peter Openshaw discusses Respiratory Syncytial Virus Infection (RSV). RSV is a common respiratory virus that usually causes mild, cold-like symptoms in most adults but it is the leading cause of hospitalisation in babies Step into the world of groundbreaking medical research with the latest episode of our podcast as Sir Andrew Pollard engages in a riveting conversation with the esteemed Professor Peter Openshaw from Imperial University. Peter Openshaw is a respiratory physician and mucosal immunologist researcher, studying how the immune system both protects against viral infection but also causes disease. He has run studies of human experimental infection of volunteers since 2008 and is Director of the HIC-Vac consortium established to accelerate vaccine development for pathogens of high global impact.
Delving deep into the realm of Respiratory Syncytial Virus (RSV) infection, this episode unveils the complexities of a common respiratory virus that can escalate into a serious health concern. RSV is a common respiratory virus that usually causes mild, cold-like symptoms in most adults but it can become more severe and it is the leading cause of hospitalisation in babies.
In this illuminating dialogue, listeners are treated to a comprehensive exploration of RSV, from its seemingly innocuous cold-like symptoms to its potential for severe illness, particularly in vulnerable populations. The conversation navigates through Professor Openshaw's early investigations into immune responses, his fascination with inflammatory reactions, and the transformative advancements witnessed in RSV medical research over the years.
As the episode progresses, attention turns to the horizon of medical innovation, with a thoughtful examination of the challenges inherent in vaccine trials and the tantalising prospect of novel treatments for infectious diseases like RSV. Join Sir Andrew Pollard and Professor Peter Openshaw as they peer into the future, offering a glimpse of what lies ahead in the relentless pursuit of conquering respiratory ailments. Creative Commons Attribution-Non-Commercial-Share Alike 2.0 UK: England & Wales; http://creativecommons.org/licenses/by-nc-sa/2.0/uk/
Sir Andrew Pollard talks to Sir Pascal Soriot, the CEO of AstraZeneca about their pandemic partnership to develop the AstraZeneca/Oxford vaccine. Over three billion vaccines have been delivered, saving six and a half million lives. It’s a reunion in this episode of the Oxford Colloquy, as Sir Andrew Pollard talks to Sir Pascal Soriot, the CEO of AstraZeneca (AZ), about their pandemic partnership to develop the AstraZeneca/Oxford vaccine. Although, as you’ll discover, they have more than vaccines in common.
From his early childhood in a relatively poor suburb of Paris, that included a love of horses, Sir Pascal talks about his first career, as a vet. But a desire to explore the world led him to the pharmaceutical industry, human health, and eventually to the top job at AZ.
With AZ now one of the fastest growing global pharmaceutical companies, Sir Pascal spends much of his time travelling. With a workstation at every site, and a ‘water cooler’ style of leadership, he keeps his ear to the ground and across vast operations.
Sir Pascal puts this period of rapid growth down to a combination of following the science, putting patients at the heart of drug development, and a well-defined focus on cancer, cardio-vascular disease, respiratory disease and more recently, rare disease.
It was early on in the pandemic that Sir Pascal realised that COVID-19 was likely to be a very big problem. He describes AZ’s very modest start – supplying masks and looking at repurposing existing drugs for treatment. But he was then introduced to Oxford’s vaccine scientists by Regius Professor of Medicine, Sir John Bell, and work together began.
Sir Pascal describes the AZ/Oxford partnership as very successful – a marriage of scientific expertise, with large-scale manufacturing and distribution skills. Both Sir Andrew and Sir Pascal note the sense of pride felt among all those involved at delivering three billion vaccines that have saved over six and a half million lives around the world. Creative Commons Attribution-Non-Commercial-Share Alike 2.0 UK: England & Wales; http://creativecommons.org/licenses/by-nc-sa/2.0/uk/
The Oxford Colloquy
Professor Peter Openshaw discusses Respiratory Syncytial Virus Infection (RSV). RSV is a common respiratory virus that usually causes mild, cold-like symptoms in most adults but it is the leading cause of hospitalisation in babies Step into the world of groundbreaking medical research with the latest episode of our podcast as Sir Andrew Pollard engages in a riveting conversation with the esteemed Professor Peter Openshaw from Imperial University. Peter Openshaw is a respiratory physician and mucosal immunologist researcher, studying how the immune system both protects against viral infection but also causes disease. He has run studies of human experimental infection of volunteers since 2008 and is Director of the HIC-Vac consortium established to accelerate vaccine development for pathogens of high global impact.
Delving deep into the realm of Respiratory Syncytial Virus (RSV) infection, this episode unveils the complexities of a common respiratory virus that can escalate into a serious health concern. RSV is a common respiratory virus that usually causes mild, cold-like symptoms in most adults but it can become more severe and it is the leading cause of hospitalisation in babies.
In this illuminating dialogue, listeners are treated to a comprehensive exploration of RSV, from its seemingly innocuous cold-like symptoms to its potential for severe illness, particularly in vulnerable populations. The conversation navigates through Professor Openshaw's early investigations into immune responses, his fascination with inflammatory reactions, and the transformative advancements witnessed in RSV medical research over the years.
As the episode progresses, attention turns to the horizon of medical innovation, with a thoughtful examination of the challenges inherent in vaccine trials and the tantalising prospect of novel treatments for infectious diseases like RSV. Join Sir Andrew Pollard and Professor Peter Openshaw as they peer into the future, offering a glimpse of what lies ahead in the relentless pursuit of conquering respiratory ailments. Creative Commons Attribution-Non-Commercial-Share Alike 2.0 UK: England & Wales; http://creativecommons.org/licenses/by-nc-sa/2.0/uk/
